Quick Answer
Taysha Gene Therapies, Inc. reported Long-Term Debt of $50.11 million for fiscal year 2025.
Taysha Gene Therapies, Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2025 | $50.11M | +14.0% |
| 2024 | $43.94M | +8.5% |
| 2023 | $40.51M | +6.7% |
| 2022 | $37.97M | +2.1% |
| 2021 | $37.19M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $50.85M | +18.3% | +23.9% |
| June 30, 2025 | $41.05M | +8.5% | -3.3% |
| March 31, 2025 | $42.45M | +4.8% | -3.4% |
| December 31, 2024 | $43.94M | +8.5% | +2.3% |
| September 30, 2024 | $42.97M | +11.5% | +13.6% |
| June 30, 2024 | $37.84M | -1.4% | -6.6% |
| March 31, 2024 | $40.51M | +6.2% | +0.0% |
| December 31, 2023 | $40.51M | +6.7% | +5.1% |
- Taysha Gene Therapies, Inc. showed an increase of +14.0% in Long-Term Debt compared to the prior fiscal year.
- Over the 2021–2025 period, Taysha Gene Therapies, Inc.’s long-term debt has grown by 34.7% (from $37.19 million to $50.11 million).
- The most recent figure is from Taysha Gene Therapies, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: